Bal Pharma Limited (BALPHARMA) - Net Assets

Latest as of September 2025: Rs783.30 Million INR ≈ $8.47 Million USD

Based on the latest financial reports, Bal Pharma Limited (BALPHARMA) has net assets worth Rs783.30 Million INR (≈ $8.47 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs3.49 Billion ≈ $37.78 Million USD) and total liabilities (Rs2.71 Billion ≈ $29.31 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Bal Pharma Limited asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets Rs783.30 Million
% of Total Assets 22.42%
Annual Growth Rate 4.71%
5-Year Change 45.08%
10-Year Change 41.45%
Growth Volatility 8.87

Bal Pharma Limited - Net Assets Trend (2006–2025)

This chart illustrates how Bal Pharma Limited's net assets have evolved over time, based on quarterly financial data. Also explore BALPHARMA current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Bal Pharma Limited (2006–2025)

The table below shows the annual net assets of Bal Pharma Limited from 2006 to 2025. For live valuation and market cap data, see Bal Pharma Limited (BALPHARMA) market capitalisation.

Year Net Assets Change
2025-03-31 Rs774.04 Million
≈ $8.37 Million		 +11.76%
2024-03-31 Rs692.61 Million
≈ $7.49 Million		 +8.73%
2023-03-31 Rs637.02 Million
≈ $6.89 Million		 +8.91%
2022-03-31 Rs584.92 Million
≈ $6.33 Million		 +9.63%
2021-03-31 Rs533.54 Million
≈ $5.77 Million		 +17.68%
2020-03-31 Rs453.38 Million
≈ $4.90 Million		 -24.71%
2019-03-31 Rs602.21 Million
≈ $6.51 Million		 +0.03%
2018-03-31 Rs602.01 Million
≈ $6.51 Million		 +0.28%
2017-03-31 Rs600.31 Million
≈ $6.49 Million		 +9.70%
2016-03-31 Rs547.22 Million
≈ $5.92 Million		 -0.81%
2015-03-31 Rs551.68 Million
≈ $5.97 Million		 +10.23%
2014-03-31 Rs500.50 Million
≈ $5.41 Million		 +12.17%
2013-03-31 Rs446.18 Million
≈ $4.83 Million		 +11.39%
2012-03-31 Rs400.56 Million
≈ $4.33 Million		 +10.73%
2011-03-31 Rs361.75 Million
≈ $3.91 Million		 +1.16%
2010-03-31 Rs357.62 Million
≈ $3.87 Million		 -3.95%
2009-03-31 Rs372.35 Million
≈ $4.03 Million		 +6.29%
2008-03-31 Rs350.32 Million
≈ $3.79 Million		 +4.88%
2007-03-31 Rs334.02 Million
≈ $3.61 Million		 +3.41%
2006-03-31 Rs323.02 Million
≈ $3.49 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Bal Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 27310400000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Retained Earnings Rs273.10 Million 35.28%
Common Stock Rs159.21 Million 20.57%
Other Comprehensive Income Rs22.07 Million 2.85%
Other Components Rs319.78 Million 41.31%
Total Equity Rs774.16 Million 100.00%

Bal Pharma Limited Competitors by Market Cap

The table below lists competitors of Bal Pharma Limited ranked by their market capitalization.

Company Market Cap
Winamp Group SA
PA:ALPET
 $13.13 Million
WooGene B&G Co. Ltd
KQ:018620
 $13.13 Million
High Coast Distillery AB
ST:HIGHCO-B
 $13.13 Million
Euro Manganese Inc
AU:EMN
 $13.14 Million
IntegraFin Holdings plc
LSE:IHP
 $13.10 Million
Integritas Viager SA
PA:MLVIE
 $13.10 Million
Barunson Co. Ltd
KQ:018700
 $13.09 Million
Caring Brands, Inc. Common Stock
NASDAQ:CABR
 $13.08 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Bal Pharma Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 692,943,000 to 774,159,000, a change of 81,216,000 (11.7%).
  • Net income of 72,154,000 contributed positively to equity growth.
  • Dividend payments of 19,105,000 reduced retained earnings.
  • Share repurchases of 8,069,000 reduced equity.
  • New share issuances of 1,412,000 increased equity.
  • Other comprehensive income increased equity by 17,976,000.
  • Other factors increased equity by 16,848,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Rs72.15 Million +9.32%
Dividends Paid Rs19.11 Million -2.47%
Share Repurchases Rs8.07 Million -1.04%
Share Issuances Rs1.41 Million +0.18%
Other Comprehensive Income Rs17.98 Million +2.32%
Other Changes Rs16.85 Million +2.18%
Total Change Rs- 11.72%

Book Value vs Market Value Analysis

This analysis compares Bal Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.44x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 2.36x to 1.44x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2006-03-31 Rs32.31 Rs76.21 x
2007-03-31 Rs31.98 Rs76.21 x
2008-03-31 Rs32.63 Rs76.21 x
2009-03-31 Rs35.30 Rs76.21 x
2010-03-31 Rs33.97 Rs76.21 x
2011-03-31 Rs34.35 Rs76.21 x
2012-03-31 Rs38.04 Rs76.21 x
2013-03-31 Rs42.20 Rs76.21 x
2014-03-31 Rs45.43 Rs76.21 x
2015-03-31 Rs42.61 Rs76.21 x
2016-03-31 Rs42.65 Rs76.21 x
2017-03-31 Rs44.44 Rs76.21 x
2018-03-31 Rs45.86 Rs76.21 x
2019-03-31 Rs47.02 Rs76.21 x
2020-03-31 Rs36.99 Rs76.21 x
2021-03-31 Rs37.74 Rs76.21 x
2022-03-31 Rs38.72 Rs76.21 x
2023-03-31 Rs40.66 Rs76.21 x
2024-03-31 Rs43.84 Rs76.21 x
2025-03-31 Rs53.09 Rs76.21 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Bal Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 9.32%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 2.38%
  • • Asset Turnover: 0.90x
  • • Equity Multiplier: 4.34x
  • Recent ROE (9.32%) is above the historical average (5.01%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2006 10.34% 4.99% 0.76x 2.73x Rs1.10 Million
2007 6.04% 2.87% 0.78x 2.71x Rs-13.23 Million
2008 8.16% 3.33% 0.79x 3.11x Rs-6.46 Million
2009 8.04% 2.89% 0.85x 3.26x Rs-7.31 Million
2010 -4.00% -1.35% 0.86x 3.47x Rs-50.05 Million
2011 1.13% 0.36% 0.84x 3.74x Rs-32.10 Million
2012 9.38% 2.69% 0.99x 3.52x Rs-2.49 Million
2013 9.60% 2.90% 0.99x 3.36x Rs-1.78 Million
2014 10.13% 2.84% 1.16x 3.09x Rs673.43K
2015 6.57% 1.94% 1.14x 2.97x Rs-18.92 Million
2016 2.56% 0.71% 0.94x 3.84x Rs-40.85 Million
2017 3.15% 0.87% 0.99x 3.66x Rs-43.13 Million
2018 4.28% 1.33% 0.83x 3.87x Rs-37.17 Million
2019 5.68% 1.68% 0.86x 3.92x Rs-28.76 Million
2020 -23.31% -7.14% 0.72x 4.55x Rs-174.61 Million
2021 8.85% 1.92% 1.03x 4.48x Rs-6.16 Million
2022 9.57% 2.00% 1.08x 4.44x Rs-2.51 Million
2023 4.03% 0.85% 0.97x 4.91x Rs-38.07 Million
2024 10.67% 2.18% 1.06x 4.61x Rs4.63 Million
2025 9.32% 2.38% 0.90x 4.34x Rs-5.26 Million

Industry Comparison

This section compares Bal Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $23,713,303,062
  • Average return on equity (ROE) among peers: 8.81%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Bal Pharma Limited (BALPHARMA) Rs783.30 Million 10.34% 3.46x $13.12 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) $988.60 Million 6.59% 1.36x $27.93 Million
Aarti Drugs Limited (AARTIDRUGS) $6.52 Billion 21.67% 1.42x $371.43 Million
Aarti Pharmalabs Limited (AARTIPHARM) $19.90 Billion 13.69% 0.46x $725.68 Million
Abbott India Limited (ABBOTINDIA) $36.99 Billion 32.48% 0.40x $5.85 Billion
Ajanta Pharma Limited (AJANTPHARM) $1.16 Billion 12.69% 1.32x $3.81 Billion
Akums Drugs and Pharmaceutical (AKUMS) $6.25 Billion -40.39% 3.91x $906.19 Million
Alkem Laboratories Limited (ALKEM) $88.47 Billion 18.60% 0.59x $6.98 Billion
Amrutanjan Health Care Limited (AMRUTANJAN) $1.46 Billion 16.82% 0.29x $178.52 Million
Alembic Pharmaceuticals Limited (APLLTD) $51.90 Billion 11.24% 0.50x $1.60 Billion
Aurobindo Pharma Limited (AUROPHARMA) $23.50 Billion -5.26% 1.65x $8.73 Billion

About Bal Pharma Limited

NSE:BALPHARMA India Drug Manufacturers - Specialty & Generic
Market Cap
$13.12 Million
Rs1.21 Billion INR
Market Cap Rank
#26203 Global
#1467 in India
Share Price
Rs76.21
Change (1 day)
-0.05%
52-Week Range
Rs60.42 - Rs106.59
All Time High
Rs151.23
Categories
Companies in India Drug Manufacturers - Specialty & Generic
About

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Az… Read more